Vasopressin
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Vasopressin: From Unrecorded Original Indication to Congenital Prothrombin Deficiency
One-Sentence Summary
Vasopressin (DrugBank ID DB00067) has no recorded original indication or mechanism-of-action data in this evidence pack, and it currently holds no marketing authorization in Taiwan (未上市). The TxGNN model predicts potential efficacy for Congenital Prothrombin Deficiency, but this is supported only by 0 clinical trials and 3 indirectly related publications (case reports/review) — and the repurposing rationale itself flags a likely drug/disease entity-confusion issue that significantly weakens the credibility of this prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no original indication recorded in this evidence pack |
| Predicted New Indication | Congenital Prothrombin Deficiency |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L4 |
| US Market Status | Not Marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for vasopressin is not available in this evidence pack (original_moa: [Data Gap]). Without an established MOA, it is not possible to build a direct mechanistic link between vasopressin and congenital prothrombin (Factor II) deficiency.
More importantly, the repurposing rationale supplied with this candidate flags a critical concern: the cited literature actually discusses desmopressin (DDAVP) — a selective V2-receptor analog of vasopressin — which promotes release of von Willebrand factor (vWF) and Factor VIII, not vasopressin itself. In addition, the disease context in the literature (Factor V/VIII deficiency, acquired hemophilia A) differs from the predicted target (congenital prothrombin/Factor II deficiency), which sits further downstream in the common coagulation pathway and has no established relationship to vWF/FVIII release mechanisms.
This double mismatch — drug (vasopressin vs. desmopressin) and disease (FV/FVIII deficiency vs. prothrombin deficiency) — suggests the high TxGNN score may reflect a knowledge-graph node confusion between vasopressin and desmopressin rather than a genuine pharmacological signal. This substantially weakens the case for treating this as a credible mechanistic hypothesis at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21115138 | 2011 | Review | Autoimmunity Reviews | Reviews acquired hemophilia A (autoantibodies against Factor VIII); does not discuss vasopressin or prothrombin deficiency directly |
| 2607619 | 1989 | Case Report | Rinsho Ketsueki (Jpn J Clin Hematol) | DDAVP administration in a patient with congenital combined Factor V and Factor VIII deficiency |
| 1942544 | 1991 | Case Report | Rinsho Ketsueki (Jpn J Clin Hematol) | Cesarean section managed with Factor VIII concentrate replacement in a pregnant patient with combined FV/FVIII deficiency |
Note: None of the above literature discusses vasopressin (as opposed to desmopressin) or congenital prothrombin (Factor II) deficiency specifically; relevance to this candidate is indirect at best.
US Market Information
This drug currently holds no marketing authorization in Taiwan (市場狀態：未上市). No license records are available in this evidence pack (total_licenses: 0).
Additional Predicted Indication (Not Prioritized)
The evidence pack also includes a second, lower-ranked candidate: drug-induced osteoporosis (TxGNN score 99.62%, Evidence Level L5, recommendation Hold). This candidate has no supporting clinical trials or literature and no known mechanistic pathway linking vasopressin’s known receptor activity (V1a/V1b/V2) to bone metabolism. It is a model-prediction-only hypothesis and requires independent mechanistic validation before any further evaluation.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA label warnings/contraindications and drug interaction data are marked as a Blocking data gap in this evidence pack — see Conclusion below.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- The evidence base for the top prediction (congenital prothrombin deficiency) is weak — Evidence Level L4, zero clinical trials, and only 3 indirectly relevant case reports/review articles.
- The repurposing rationale itself identifies a likely drug-entity confusion (vasopressin vs. desmopressin) and disease-target mismatch (Factor V/VIII deficiency vs. prothrombin deficiency), undermining mechanistic plausibility.
- A Blocking data gap (TFDA label warnings/contraindications, DG001) prevents this candidate from entering safety pre-assessment (S1).
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain TFDA/original market label warnings and contraindications before any S1 safety pre-assessment
- Resolve DG002: retrieve vasopressin MOA via DrugBank API to enable a legitimate mechanistic assessment
- Clarify whether the TxGNN prediction stems from a vasopressin/desmopressin node confusion in the knowledge graph; consider re-running the prediction with disambiguated drug entities
- Conduct an independent literature review specific to vasopressin (not desmopressin) in coagulation disorders
- If pursuing the prothrombin deficiency indication, obtain mechanistic studies specifically linking vasopressin (not its analogs) to Factor II regulation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.